| Quantity: | |
|---|---|
Clinically relevant – Mimics human SjS: reduced salivary flow, anti-salivary gland antibodies, glandular lymphocytic infiltration.
Quantifiable endpoints – Salivary flow rate measurement, autoantibody titers, histopathology of salivary and lacrimal glands.
Translational value – Ideal for testing biologics, JAK inhibitors, and immunomodulators targeting autoimmune exocrinopathy.
Multi-system evaluation – Assess both glandular and extra-glandular manifestations (arthritis, lupus-like features if present).
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
Representative data from our NHP SjS model:
Salivary Gland Protein Induced NHP SjS Model
• Efficacy testing of biologics (anti-CD20, anti-BAFF, anti-IL-6), JAK inhibitors, and immunomodulators
• Target validation for autoimmune exocrinopathy pathways
• Biomarker discovery (autoantibodies, salivary proteins, inflammatory mediators)
• Mechanism of action (MOA) studies
• IND-enabling toxicology and safety pharmacology studies
Parameter | Specification |
Species | Cynomolgus macaque (Macaca fascicularis) |
Induction method | Immunization with salivary gland protein extract emulsified in adjuvant (e.g., CFA/IFA), with booster injections |
Study duration | 8–14 weeks (induction + treatment phase) |
Key endpoints | Salivary flow rate, anti-salivary gland protein antibodies (IgG), histopathology of salivary/lacrimal glands (focus score), tear production (Schirmer's test), optional: cytokine profiling, immune cell phenotyping |
Data package | Raw data, analysis reports, histology slides, bioinformatics (optional) |
Q: How is the NHP SjS model induced?
A: By immunization with salivary gland protein extract in adjuvant, which triggers an autoimmune response against salivary and lacrimal glands, leading to reduced secretory function.
Q: What are the key similarities with human Sjögren's syndrome?
A: The model exhibits reduced salivary flow, elevated autoantibodies against salivary gland antigens, and lymphocytic infiltration of salivary glands, closely resembling human SjS pathology.
Q: Can this model be used for IND-enabling studies?
A:Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different adjuvants, dosing regimens)?
A: Absolutely. Our scientific team tailors immunization protocols, treatment schedules, and endpoint analyses to your specific drug candidate.